Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study.

نویسندگان

  • S I R Noble
  • A Nelson
  • C Turner
  • I G Finlay
چکیده

OBJECTIVE To find out what inpatients with advanced cancer who are receiving palliative care think about the effect of thromoprophylaxis on overall quality of life. DESIGN Qualitative study using audiotaping of semistructured interviews. SETTING Regional cancer centre in Wales. PARTICIPANTS 28 inpatients with advanced metastatic cancer receiving palliative care and low molecular weight heparin. MAIN OUTCOME MEASURES Recurring themes on the effect of thromboprophylaxis on overall quality of life. RESULTS Major emerging themes showed that patients knew about the risks of venous thromboembolism and the purpose of treatment with heparin. Media coverage had raised awareness about venous thromboembolism, and many had previous experience of thromboprophylaxis. All found low molecular weight heparin an acceptable intervention, and many said that it improved their quality of life by giving them a feeling of safety and reassurance. Antiembolic stockings were considered uncomfortable and had a negative impact on quality of life. Patients were concerned that because they had advanced disease they might not be eligible for thromboprophylaxis. CONCLUSION Low molecular weight heparin is acceptable to inpatients with advanced cancer receiving palliative care and has a positive impact on overall quality of life. Antiembolic stockings are an unacceptable intervention in this patient group. Guidelines on thromboprophylaxis are urgently needed for palliative care inpatient units and hospices.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Primary thromboprophylaxis in the palliative care setting: a qualitative systematic review.

Symptomatic venous thromboembolism (VTE) occurs in 15% of patients with advanced malignancy. Primary thromboprophylaxis using low-molecular-weight heparin (LMWH) is supported by Level 1A evidence but is under-utilized in the palliative setting. A systematic search was performed of Medline, Cochrane Library, EMBASE, AMED, and Web of Science for papers published between 1960 and January 2010 usin...

متن کامل

Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review.

PURPOSE The study aimed to systematically review the effect of low-molecular-weight heparin (LMWH) thromboprophylaxis in medical-surgical critically ill patients in the intensive care unit. METHODS In duplicate and independently, we searched for relevant articles using MEDLINE and EMBASE; we also contacted experts and reviewed reference lists. For included studies, we abstracted data on study...

متن کامل

Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.

OBJECTIVE To compare the cost effectiveness of prophylaxis with a low-molecular-weight heparin with that of prophylaxis with unfractionated heparin for the prevention of venous thromboembolism in acutely ill medical inpatients. STUDY DESIGN Cost-effectiveness analysis based on decision-tree model. PARTICIPANTS AND METHODS A hypothetical cohort of 10 000 patients was assumed to receive eithe...

متن کامل

Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study

BACKGROUND Venous thromboembolism is a common complication of cancer and its treatments. Treatment of cancer-associated thrombosis (CAT) differs from treatment of thrombosis in noncancer patients, requiring a daily injection of low-molecular-weight heparin (LMWH) for 6 months instead of an oral anticoagulant. Previous research suggested LMWH is an acceptable intervention in the treatment of CAT...

متن کامل

Thromboprophylaxis in the cancer patient.

Thrombosis is a common complication in patients with malignant disease resulting from tumour elaboration of procoagulants and subsequent activation of intravascular coagulation. Cancer therapies (operation, chemotherapy and the use of central venous lines) further heighten the risk of thrombosis. The risk of thrombosis in cancer operations is of sufficient magnitude to necessitate routine throm...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • BMJ

دوره 332 7541  شماره 

صفحات  -

تاریخ انتشار 2006